- Home
- FIGR vs AXSM Comparison
FIGR vs AXSM Comparison
Compare FIGR & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FIGR | AXSM |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.0B |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FIGR | AXSM |
|---|---|---|
| Price | $72.29 | $184.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 21 |
| Target Price | $56.89 | ★ $189.57 |
| AVG Volume (30 Days) | ★ 3.8M | 806.9K |
| Earning Date | 11-19-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | $382,600,000.00 | ★ $561,263,000.00 |
| Revenue This Year | $74.99 | $67.10 |
| Revenue Next Year | $34.64 | $58.73 |
| P/E Ratio | $279.72 | ★ N/A |
| Revenue Growth | ★ 137.06 | 65.83 |
| 52 Week Low | $30.01 | $86.99 |
| 52 Week High | $76.57 | $184.40 |
Technical Indicators
Market Signals| Indicator | FIGR | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 68.77 |
| Support Level | N/A | $172.05 |
| Resistance Level | N/A | $179.00 |
| Average True Range (ATR) | 0.00 | 8.01 |
| MACD | 0.00 | 0.72 |
| Stochastic Oscillator | 0.00 | 94.81 |
Price Performance
Historical ComparisonAbout FIGR Figure Technology Solutions Inc.
Figure Technology Solutions Inc is a suite of blockchain-based products and solutions centered around the vision of promoting efficiency and liquidity in financial markets. The company offers a technology-enabled loan origination system and paired this system with a distribution marketplace, Figure Connect, providing access to a deep and broad pool of capital markets partners.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.